<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113017</url>
  </required_header>
  <id_info>
    <org_study_id>XYEYY20210728</org_study_id>
    <nct_id>NCT05113017</nct_id>
  </id_info>
  <brief_title>The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery</brief_title>
  <acronym>SMILE</acronym>
  <official_title>To Evaluate the Effectiveness and Safety of Stereotactic Radiotherapy (SBRT) in the Treatment of Patients With Residual Malignant Pulmonary Nodules After Lung Cancer Surgery: A Multi-center, Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fang Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual&#xD;
      malignant pulmonary nodules after lung cancer, and is committed to providing new treatment&#xD;
      options for patients with multiple primary malignant pulmonary nodules who cannot tolerate&#xD;
      multiple operations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 14, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Effectiveness of SBRT</measure>
    <time_frame>2-year</time_frame>
    <description>Local control rate of cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of SBRT</measure>
    <time_frame>2-year</time_frame>
    <description>Treatment-related adverse event</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2-year</time_frame>
    <description>Survival rate without local recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>2-year</time_frame>
    <description>Survival rate without distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>2-year</time_frame>
    <description>Progression-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>2-year</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>The Efficacy and Safety of SBRT in MPLC</condition>
  <arm_group>
    <arm_group_label>SBRT group</arm_group_label>
    <description>Patients with residual lung nodules are treated with SBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO Intervention</intervention_name>
    <description>NO Intervention</description>
    <arm_group_label>SBRT group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inoperable residual malignant nodules after early multiple primary lung&#xD;
        cancer surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (1) Age 18-75 years old; (2) ECOG score 0-2 points; (3) Chest CT showed at least two lung&#xD;
        nodules (pure ground glass, partial solid or solid nodules); (4) At least one lesion has&#xD;
        been pathologically diagnosed as lung cancer (T1N0M0-T1N1M0); (5) At least one residual&#xD;
        pulmonary nodule has been diagnosed pathologically or multidisciplinary diagnosis and&#xD;
        treatment (MDT) discussed and considered as a primary malignant pulmonary nodule; (6) The&#xD;
        residual lung nodules are inoperable or operable but the patient refuses to be surgically&#xD;
        removed; (7) Have self-consciousness and can sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        (1) There are metastatic pulmonary nodules; (2) Have received chest radiotherapy in the&#xD;
        past; (3) Lymph node metastasis or distant metastasis; (4) The tumor is located in the&#xD;
        proximal bronchial tree area. The proximal bronchial tree is defined as carina, left and&#xD;
        right main bronchus, left and right upper lobe bronchus, middle bronchus, right middle lobe&#xD;
        bronchus, lingual bronchus, left and right lower lobe bronchi; the proximal bronchial tree&#xD;
        area is defined as surrounding the proximal bronchial tree in all directions The area&#xD;
        within 2cm above; (5) Pneumonectomy patients; (6) Severe primary diseases such as heart,&#xD;
        liver, kidney, hematopoietic system, etc.; (7) Women during pregnancy and lactation; (8)&#xD;
        Active period of the human immunodeficiency virus (HIV) infection; (9) Those with active&#xD;
        systemic infection, pneumonia, tuberculosis, and pericarditis; (10) There is a history of&#xD;
        psychotropic drug abuse or drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunhong Hu, professor</last_name>
    <phone>+86 13508486908</phone>
    <email>huchunh5829@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncology Departmentï¼ŒSecond Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunhong Hu, professor</last_name>
      <phone>+86 13508486908</phone>
      <email>huchunh5829@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second Xiangya Hospital of Central South University</investigator_affiliation>
    <investigator_full_name>Fang Wu</investigator_full_name>
    <investigator_title>Second Xiangya Hospital of Central South University</investigator_title>
  </responsible_party>
  <keyword>SBRT, MPLC, Efficacy, Safety</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

